Word: breasted
(lookup in dictionary)
(lookup stats)
Dates: during 1990-1999
Sort By: most recent first
(reverse)
...bones in her hips, thighs and spine were losing mass. But Levin, whose mother also suffered from the general weakening of the bones known as osteoporosis, didn't want to take estrogen. Although the hormone can reverse the bone-weakening process, it may also increase the risk of breast cancer. So Levin volunteered for a study of an experimental drug called raloxifene, which may confer most of the benefits of estrogen therapy without the risks. Although her doctors won't tell her whether she's on the drug or the placebo, Levin is pretty sure she's getting the real...
...estrogen is the closest thing to a perfect antiaging potion. It moisturizes the skin, maintains strong bones and protects against heart disease. It may even delay the onset of Alzheimer's disease. There is one big catch, however: estrogen may increase as much as 40% the risk of developing breast or uterine cancer...
Scientists first became interested in designer estrogens in the early 1990s. While studying a powerful new anticancer drug called tamoxifen, which works by blocking estrogen's ability to stimulate breast tissue, they discovered that it also helped prevent osteoporosis. The drug seemed to act like an estrogen in the bone but an anti-estrogen in the breast. Unfortunately, it also acted like an estrogen in the uterus, dramatically increasing the risk of uterine cancer. So researchers set out to find a chemical cousin of tamoxifen that would be easier on the uterus...
Raloxifene seemed to fit the bill. Studies showed it increased older women's bone density 1% to 2%. It also seemed to reduce the incidence of breast cancer--by 58% over the course of a year in one study--and to cut the level of so-called bad cholesterol in the blood. Best of all, researchers have found no hint of trouble in their patients' uterine or breast tissue--at least...
Just as troubling, a woman who has taken raloxifene and then develops breast cancer may reduce her options for fighting the malignancy. Because raloxifene is a distant cousin of the cancer-fighting drug tamoxifen, some scientists are worried that any tumor cells that survive are likely to be resistant to tamoxifen as well...